

INACTIVATED *VIBRIO CHOLERA* VACCINE IN TABLETS

Claims

What we claim is:

1. A vaccine composition for cholera composed of:
 - a. Inactivated cells of *Vibrio cholera*
 - b. Agglutinants
 - c. Lubricants
 - d. Coating substance
 - e. Filling substance
 - f. Disintegrating substance
2. The vaccine composition described in Claim 1, with inactivated cells consisting of attenuated strains of *Vibrio cholerae*.
3. The vaccine composition described in Claim 2, with inactivated cells belonging to the serum group O139.
4. The vaccine composition described in Claim 3, with inactivated cells belonging to the serum group O1.
5. The vaccine composition described in Claim 4, with El Tor or Classic type cells.
6. The vaccine composition described in Claim 5, the inactivated cells belonging to the Ogawa or Inaba serum type.
7. The vaccine composition described in Claim 2, the inactivated cells consisting of wild strains of *Vibrio cholerae*.
8. The vaccine composition described in Claim 7, the inactivated cells belonging to the serum group O139.
9. The vaccine composition described in Claim 8, the inactivated cells belonging to the serum group O1.
10. The vaccine composition described in Claim 9, with El Tor or Classic bio-type cells.
11. The vaccine composition described in Claim 10, with Ogawa or Inaba serum type cells
12. The vaccine composition described in Claims 1 to 11, containing between 5×10^9 and 10^{11} cells per tablet.
13. The vaccine composition described in Claim 1, with povidone, gelatin, or carboxymethylcellulose as an agglutinant.
14. The vaccine composition described in Claim 13, with the agglutinants found at a concentration between 1 and 5% of the tablet's total mass.

15. The vaccine composition described in Claim 1, with sodium carboxymethylstarch, magnesium stearate, silicon dioxide, or talc as a lubricants
16. The vaccine composition described in Claim 1, the lubricants found at a concentration between 0.25 and 1.5% of the tablet's total mass.
17. The vaccine composition described in Claim 1, with cellulose acetophtalate, cellulose diethylphthalate, lacquer at 10% or titanium dioxide as a coating substance.
18. The vaccine composition described in Claim 17, with the coating substance found at a concentration between 1 and 2% of the tablet's total mass.
19. The vaccine composition described in Claim 1, with lactose or cornstarch as filling substance.
20. The vaccine composition described in Claim 19, the filling substance found at a concentration between 65 and 80% that of tablet's total mass.
21. The vaccine composition described in Claim 1, with sodium croscarmellose, cornstarch or micro-crystalline cellulose as a disintegrating substance.
22. The vaccine composition described in Claim 21, the disintegrating substance found at a concentration between 1 and 6% that of the tablet's total mass.